Finasteride Tablet, Film Coated
Product Images NDC 16729-090

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 16729-090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label-30 Tablets (Finasteride 30 Label)

Finasteride Tablets USP 5 mg film-coated oral tablets packaging label. The label includes usage warnings, storage instructions, and manufacturer information for Accord Healthcare, Inc. The package contains 30 tablets with an NDC of 16729-090. It also includes barcodes and the Accord logo.*

FDA Label Image

Structure (Finasteride Fig 1)

Chemical structure of finasteride, the active ingredient in Finasteride 5 mg film-coated tablets by Accord Healthcare, Inc. The diagram shows the molecular framework including characteristic rings and functional groups.*

FDA Label Image

Image Of Figure 1 (Finasteride Fig 2)

A line graph comparing the mean change from baseline between Finasteride and placebo groups over four years, with sample sizes indicated for each time point. The y-axis shows mean change with standard error, and the x-axis shows time from baseline through year 4. Finasteride demonstrates a greater mean change compared to placebo throughout the period.*

FDA Label Image

Image Of Figure 2 (Finasteride Fig 3)

A line graph showing the cumulative percent of patients over 48 months for Finasteride and Placebo groups. The y-axis represents percent of patients, and the x-axis shows observation time in months. Below, tables list the number of events and patients at risk per year for each group.*

FDA Label Image

Image Of Figure 3 (Finasteride Fig 4)

A line graph comparing the mean percent change from baseline over four years between placebo and Finasteride 5 mg treatment groups. The graph shows positive increase for Finasteride and negative change for placebo, with data points labeled by year and sample size at each time point.*

FDA Label Image

Image Of Figure 4 (Finasteride Fig 5)

A line graph showing the percent with event over 5.5 years from randomization comparing four groups: Placebo, Finasteride, Doxazosin, and Combination. The y-axis represents the percent with event, ranging from 0 to 25%, and the x-axis represents years from 0 to 5.5. Each group is represented by a different line and marker style, with Placebo having the highest event percent and Combination the lowest.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.